{"generic":"Bevacizumab","drugs":["Avastin","Bevacizumab"],"mono":{"0":{"id":"jw2cs0","title":"Generic Names","mono":"Bevacizumab"},"1":{"id":"jw2cs1","title":"Dosing and Indications","sub":[{"id":"jw2cs1b4","title":"Adult Dosing","mono":"<ul><li><b>Age related macular degeneration, Secondary to choroidal neovascularization:<\/b> 1.25 mg via INTRAVITREAL injection once every 4 weeks, 6 weeks, or 8 weeks continuously for 1 year (study dose)<\/li><li><b>Age related macular degeneration, Secondary to choroidal neovascularization:<\/b> 1.25 mg via INTRAVITREAL injection every 6 weeks for a total of 3 injections, followed by treatment as needed; mean 5.8 injections\/52 weeks (study dose)<\/li><li><b>Age related macular degeneration, Secondary to choroidal neovascularization:<\/b> 1.25 mg via INTRAVITREAL injection every 4 weeks for a total of 3 injections  or until macular edema, subretinal fluid and\/or pigment epithelial detachment resolved (study dose)<\/li><li><b>Age related macular degeneration, Secondary to choroidal neovascularization:<\/b> 2.5 mg via INTRAVITREAL injection every 4 weeks for a total of 3 injections (study dose)<\/li><li><b>Branch retinal vein occlusion with macular edema:<\/b> 1.25 mg via INTRAVITREAL injection 1 time, and repeated at 1 to 3 month intervals if the foveal thickness was 250 mcm or greater, or if there was persistent or recurrent macular edema; mean of 3.8 injections over 2 years (study dose)<\/li><li><b>Central retinal vein occlusion with macular edema:<\/b> 1.25 mg (0.05 mL) via intravitreal injection every 6 weeks for 24 weeks (4 injections) was used in a clinical trial<\/li><li><b>Cervical cancer, Recurrent, persistent, or metastatic:<\/b> 15 mg\/kg IV infusion on day 1 of each 21-day cycle in combination  with cisplatin 50 mg\/m(2) plus paclitaxel 135 or 175 mg\/m(2) on day 1 or topotecan 0.75 mg\/m(2) on days 1 to 3 plus paclitaxel 175 mg\/m(2) on day 1 (study dosing)<\/li><li><b>Choroidal retinal neovascularization, Secondary to pathologic myopia:<\/b> 1.25 mg\/0.05 mL INTRAVITREAL injection and monthly retreatment as needed (study dose)<\/li><li><b>Diabetic macular edema:<\/b> 1.25 mg INTRAVITREAL injection at baseline and at 6 and 12 weeks was used in a clinical trial; additional injections were permitted every 6 weeks (MAX 9 injections in first 12 months)<\/li><li><b>Epistaxis - Osler hemorrhagic telangiectasia syndrome:<\/b> single dose of 100 mg SUBMUCOSALLY (multiple intranasal injections totaling 100 mg) at initial presentation plus 100 mg nasal spray TOPICALLY as needed was administered in a clinical trial<\/li><li><b>Glioblastoma multiforme of brain, Recurrent, progressive disease following prior therapy:<\/b> 10 mg\/kg IV over 90 minutes once every 2 weeks; if tolerated, the infusion may be given over 60 minutes for the second infusion and 30 minutes for subsequent infusions<\/li><li><b>Metastatic breast cancer, HER2-negative, as first-line therapy in combination with paclitaxel:<\/b> 10 mg\/kg given as a IV infusion once every 14 days in combination with paclitaxel<\/li><li><b>Metastatic colorectal cancer, First-line therapy, in combination with oxaliplatin and capecitabine:<\/b> first-line therapy with XELOX (oxaliplatin and capecitabine), 7.5 mg\/kg IV over 30 to 90 minutes every 3 weeks was used in a clinical trial<\/li><li><b>Metastatic colorectal cancer, First- or second-line therapy, in combination with IV 5-fluorouracil-based chemotherapy:<\/b> with bolus-IFL (irinotecan, fluorouracil, leucovorin), 5 mg\/kg IV over 90 minutes once every 2 weeks; if tolerated, the infusion may be given over 60 minutes for the second infusion and 30 minutes for subsequent infusions<\/li><li><b>Metastatic colorectal cancer, First- or second-line therapy, in combination with IV 5-fluorouracil-based chemotherapy:<\/b> first-line therapy with FOLFOX-4 (oxaliplatin plus leucovorin followed by a bolus and infusional 5-fluorouracil), 5 mg\/kg IV over 30 to 90 minutes every 2 weeks was used in a clinical trial<\/li><li><b>Metastatic colorectal cancer, First- or second-line therapy, in combination with IV 5-fluorouracil-based chemotherapy:<\/b> second-line therapy with FOLFOX-4 (oxaliplatin plus leucovorin followed by a bolus and infusional 5-fluorouracil), 10 mg\/kg IV once over 90 minutes every 2 weeks; if tolerated, the infusion may be given over 60 minutes for the second infusion and 30 minutes for subsequent infusions<\/li><li><b>Metastatic colorectal cancer, In previously untreated elderly patients, ineligible for oxaliplatin- or irinotecan-based chemotherapy:<\/b> bevacizumab 7.5 mg\/kg IV on day 1 with capecitabine 1000 mg\/m(2) orally twice daily on days 1 to 14, given every 3 weeks until disease progression<\/li><li><b>Metastatic colorectal cancer, Second-line therapy, in combination with fluoropyrimidine\/irinotecan- or fluoropyrimidine\/oxaliplatin-based chemotherapy, in patients who have progressed on a first-line bevacizumab-containing regimen:<\/b> 5 mg\/kg IV once every 2 weeks or 7.5 mg\/kg IV once every 3 weeks over 90 minutes with fluoropyrimidine\/irinotecan- or fluoropyrimidine\/oxaliplatin-based chemotherapy; if tolerated, the infusion may be given over 60 minutes for the second infusion and 30 minutes for subsequent infusions<\/li><li><b>Metastatic renal cell carcinoma, In combination with interferon alfa:<\/b> 10 mg\/kg IV infusion over 90 minutes once every 2 weeks in combination with interferon alfa; interferon alfa-2a  or alfa-2b  9 million international units SUBQ 3 times per week was used in clinical trials; if bevacizumab is tolerated, the infusion may be given over 60 minutes for the second infusion and 30 minutes for subsequent infusions<\/li><li><b>Nonsquamous non-small cell lung cancer, Recurrent or metastatic, unresectable, locally advanced, first-line treatment in combination with paclitaxel and carboplatin:<\/b> 15 mg\/kg IV over 90 minutes once every 3 weeks in combination with paclitaxel and carboplatin; if tolerated, the infusion may be given over 60 minutes for the second infusion and 30 minutes for subsequent infusions; bevacizumab plus paclitaxel 200 mg\/m(2) IV and carboplatin (AUC 6) IV on day 1 once every 3 weeks for 6 cycles has been used in clinical trials; after 3  to 6 cycles of combination therapy, single-agent bevacizumab was continued until disease progression or intolerable toxicity in some patients<\/li><li><b>Ovarian cancer, Advanced, first-line therapy in combination with carboplatin and paclitaxel:<\/b> 15 mg\/kg IV infusion for cycles 2 through 22 in combination with carboplatin AUC 6 and paclitaxel 175 mg\/m(2) on day 1 every 3 weeks for 6 cycles (GOG-0218 study dose)<\/li><li><b>Ovarian cancer, Advanced, first-line therapy in combination with carboplatin and paclitaxel:<\/b> 7.5 mg\/kg every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles in combination with carboplatin AUC 5 or 6 and paclitaxel 175 mg\/m(2) IV every 3 weeks for 6 cycles (ICON7 study dose)<\/li><li><b>Ovarian cancer, Recurrent, platinum-resistant:<\/b> 10 mg\/kg IV every 2 weeks in combination with weekly IV paclitaxel, pegylated liposomal doxorubicin, or topotecan ;  paclitaxel 80 mg\/m(2) IV on days 1, 8, 15, and 22 every 4 weeks, or pegylated liposomal doxorubicin 40 mg\/m(2) IV on day 1 every 4 weeks, or topotecan 4 mg\/m(2) IV on days 1, 8, and 15 every 4 weeks until disease progression or unacceptable toxicity (AURELIA trial)<\/li><li><b>Ovarian cancer, Recurrent, platinum-resistant:<\/b> 15 mg\/kg IV every 3 weeks in combination with IV topotecan every 3 weeks; topotecan 1.25 mg\/m(2) IV on days 1 to 5 every 3 weeks until disease progression or unacceptable toxicity (AURELIA trial)<\/li><li><b>Ovarian cancer, Recurrent, platinum-sensitive:<\/b> 15 mg\/kg IV on day 1 before chemotherapy and continued after chemotherapy plus gemcitabine 1000 mg\/m(2) on days 1 and 8 and carboplatin AUC 4 mg\/mL\/min on day 1 of 21-day cycles for 6 cycles, with up to 10 cycles allowed until disease progression or unacceptable toxicity (OCEANS study dose)<\/li><\/ul>"},{"id":"jw2cs1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness of bevacizumab not established in pediatric patients<\/li><li><b>Retinopathy of prematurity:<\/b> 0.625 mg via INTRAVITREAL injection for 1 dose (study dose)<\/li><li><b>Retinopathy of prematurity:<\/b> 7 days prior to vitrectomy, 0.625 mg via INTRAVITREAL injection for 1 dose (study dose)<\/li><\/ul>"},{"id":"jw2cs1b6","title":"Dose Adjustments","mono":"<ul><li><b>hypertension, severe, not controlled:<\/b> temporarily suspend bevacizumab; discontinue with hypertensive crisis or hypertensive encephalopathy<\/li><li><b>proteinuria, moderate to severe:<\/b> temporarily suspend bevacizumab; discontinue for nephrotic syndrome<\/li><li><b>surgery:<\/b> suspend treatment with bevacizumab at least 28 days prior to elective surgery; do not restart until the surgical incision has completely healed; do not give for at least 28 days following major surgery; discontinue if wound healing complications require medical intervention<\/li><\/ul>"},{"id":"jw2cs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cervical cancer, Recurrent, persistent, or metastatic<\/li><li>Glioblastoma multiforme of brain, Recurrent, progressive disease following prior therapy<\/li><li>Metastatic colorectal cancer, First- or second-line therapy, in combination with IV 5-fluorouracil-based chemotherapy<\/li><li>Metastatic colorectal cancer, Second-line therapy, in combination with fluoropyrimidine\/irinotecan- or fluoropyrimidine\/oxaliplatin-based chemotherapy, in patients who have progressed on a first-line bevacizumab-containing regimen<\/li><li>Metastatic renal cell carcinoma, In combination with interferon alfa<\/li><li>Nonsquamous non-small cell lung cancer, Recurrent or metastatic, unresectable, locally advanced, first-line treatment in combination with paclitaxel and carboplatin<\/li><li>Ovarian cancer, Recurrent, platinum-resistant<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Age related macular degeneration, Secondary to choroidal neovascularization<\/li><li>Branch retinal vein occlusion with macular edema<\/li><li>Central retinal vein occlusion with macular edema<\/li><li>Choroidal retinal neovascularization, Secondary to pathologic myopia<\/li><li>Diabetic macular edema<\/li><li>Diabetic retinopathy<\/li><li>Epistaxis - Osler hemorrhagic telangiectasia syndrome<\/li><li>Metastatic breast cancer, HER2-negative, as first-line therapy in combination with paclitaxel<\/li><li>Metastatic breast cancer, HER2-negative, as second-line therapy in combination with other chemotherapy<\/li><li>Metastatic breast cancer, In combination with capecitabine in patients previously treated with an anthracycline and a taxane<\/li><li>Metastatic colorectal cancer, First-line therapy, in combination with oxaliplatin and capecitabine<\/li><li>Metastatic colorectal cancer, In previously untreated elderly patients, ineligible for oxaliplatin- or irinotecan-based chemotherapy<\/li><li>Neovascular glaucoma; Adjunct<\/li><li>Ovarian cancer, Advanced, first-line therapy in combination with carboplatin and paclitaxel<\/li><li>Ovarian cancer, Recurrent, platinum-sensitive<\/li><li>Retinopathy of prematurity<\/li><\/ul>"}]},"2":{"id":"jw2cs2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Gastrointestinal perforation, some cases fatal, has occurred in up to 3.2% of bevacizumab-treated patients. Bevacizumab is also associated with an increased incidence of surgical and wound healing complications, including serious and fatal complications. Discontinue bevacizumab if gastrointestinal perforation or wound dehiscence occurs. Discontinue at least 28 days prior to elective surgery. Do not initiate bevacizumab for at least 28 days after surgery and until the surgical wound is fully healed. Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, CNS hemorrhage, epistaxis, and vaginal bleeding, has occurred up to 5-fold more frequently in bevacizumab-treated patients. Do not administer bevacizumab to patients with serious hemorrhage or recent hemoptysis.<br\/>"},"3":{"id":"jw2cs3","title":"Contraindications\/Warnings","sub":[{"id":"jw2cs3b9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"jw2cs3b10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Gastrointestinal perforation, which may be serious and\/or fatal, has been reported; discontinue use if suspected<\/li><li>-- Increased risk of impaired wound healing and\/or wound dehiscence; discontinue use if suspected<\/li><li>-- Discontinue bevacizumab use at least 28 days prior to elective surgery and do not reinitiate for at least 28 days post surgery and until surgical wound is fully healed<\/li><li>-- Hemorrhage, which may be severe or fatal, including hemoptysis, gastrointestinal bleeding, CNS hemorrhage, epistaxis, and vaginal bleeding, has been reported, with an increased risk of gastrointestinal hemorrhage in elderly patients; discontinuation required<\/li><li>-- Avoid use in patients with serious hemorrhage or recent hemoptysis (0.5 teaspoon or more of red blood)<\/li><li>Cardiovascular:<\/li><li>-- Increased risk for severe (Grade 3 or 4) hypertension; monitoring required and interruption or discontinuation may be necessary<\/li><li>Gastrointestinal:<\/li><li>-- Gastrointestinal fistulae, including gastrointestinal-vaginal fistula, have been reported and may be accompanied by bowel obstruction requiring surgical interventions<\/li><li>Hematologic:<\/li><li>-- Serious and sometimes fatal arterial thrombotic events (ie, cerebral infarction, angina, transient ischemic attack, myocardial infarction) have been reported, with an increased risk in patients with a history of arterial thromboembolism, diabetes, or age greater than 65 years; discontinue use if severe event is suspected<\/li><li>-- Venous thromboembolic events have been reported, with an increased risk in patients with persistent, recurrent, or metastatic cervical cancer; permanent discontinuation required if life-threatening (grade 4) thromboembolism or pulmonary embolism occur<\/li><li>Neurologic:<\/li><li>-- Posterior reversible encephalopathy syndrome (PRES) has been reported, occurring from 16 hours up to 1 year after treatment initiation; MRI required to confirm diagnosis; discontinue use in patients developing PRES<\/li><li>-- Intracranial hemorrhage has been reported; discontinue use if suspected<\/li><li>Renal:<\/li><li>-- Nephrotic syndrome, sometimes fatal, has been reported; monitoring recommended; discontinue use if suspected<\/li><li>-- Proteinuria has been reported, with an increased risk in elderly patients; monitoring recommended and interrupt treatment for greater than or equal to 2 g of proteinuria per 24 hours<\/li><li>Reproductive:<\/li><li>-- Increased risk of ovarian failure has been reported and fertility may be impaired<\/li><li>-- Ovarian failure has been reported with concomitant modified fluorouracil\/leucovorin\/oxaliplatin (mFOLFOX) chemotherapy use in premenopausal women with colorectal cancer (unapproved use)<\/li><li>Respiratory:<\/li><li>-- Serious and\/or fatal pulmonary hemorrhage has been reported; discontinue use if suspected<\/li><li>Other:<\/li><li>-- Non-gastrointestinal fistulae (ie, tracheoesophageal, bronchopleural, biliary, vaginal, renal, bladder), which may be serious and\/or fatal, have been reported; discontinue use if fistula formation involving internal organs is suspected, permanent discontinuation is required for tracheoesophageal fistula or any grade 4 fistula<\/li><li>-- Necrotizing fascitis, sometimes fatal, has been reported, and is typically secondary to wound healing complications, gastrointestinal perforation, or fistula formation; discontinue use if suspected<\/li><li>-- Infusion reactions (ie, hypertension, hypertensive crisis, wheezing, oxygen desaturation, hypersensitivity reaction (grade 3), chest pain, headache, rigors, and diaphoresis) have been reported; if severe reaction occurs, stop infusion and institute appropriate therapy<\/li><\/ul>"},{"id":"jw2cs3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"jw2cs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jw2cs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, All grades (19% to 34%)<\/li><li><b>Dermatologic:<\/b>Hand-foot syndrome due to cytotoxic therapy<\/li><li><b>Endocrine metabolic:<\/b>Hyperglycemia (Cervical cancer, 26%), Hypomagnesemia (Cervical cancer, 24%), Weight decreased (15% to 21%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (Colorectal carcinoma, 29% to 40%), Diarrhea ((all grades), 21%; (grade 3 or greater), 1% to 34%), Indigestion (Colorectal carcinoma, 17% to 24%), Loss of appetite (34% to 43%), Stomatitis (15% to 32%), Taste sense altered (Colorectal carcinoma, 14% to 21%), Vomiting (Colorectal carcinoma, 47% to 52%)<\/li><li><b>Hematologic:<\/b>Hemorrhage, Any grade (Glioblastoma, 40%)<\/li><li><b>Immunologic:<\/b>Infectious disease (Cervical cancer, 10%; ovarian, fallopian tube, or peritoneal cancer, 10.6%; glioblastoma, 55%; non-small cell lung cancer, 13.6%)<\/li><li><b>Musculoskeletal:<\/b>Backache (Renal cell carcinoma, 12%)<\/li><li><b>Neurologic:<\/b>Asthenia (up to 70%), Headache (up to 50%)<\/li><li><b>Renal:<\/b>Proteinuria, All grades (4% to 36%)<\/li><li><b>Respiratory:<\/b>Dyspnea (Colorectal carcinoma, 25% to 26%), Epistaxis (5% to 35%), Upper respiratory infection (Colorectal carcinoma, 40% to 47%)<\/li><li><b>Other:<\/b>Fatigue (Cervical cancer, 80%; glioblastoma, 45%; renal cell carcinoma, 33%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Arterial thromboembolism (up to 8.5%), Congestive heart failure, Hypertension, Grade 3 or more (5% to 18%), Hypertensive encephalopathy, Myocardial infarction<\/li><li><b>Dermatologic:<\/b>Impaired wound healing (3% to 15%), Necrotizing fasciitis, Wound dehiscence (0.8%)<\/li><li><b>Endocrine metabolic:<\/b>Hypokalemia<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (50% to 61% (all grades); 8% to 11.9% (grade 3 or greater)), Gastrointestinal fistula (Cervical cancer, 8.3%), Gastrointestinal hemorrhage (Colorectal carcinoma, 19% to 24%), Gastrointestinal perforation (0.3 to 3.2%), Hematemesis, Tracheoesophageal fistula<\/li><li><b>Hematologic:<\/b>Deep venous thrombosis (Colorectal carcinoma, 6% to 9%), Febrile neutropenia (non-small cell lung cancer, 5%), Hemorrhage, Grade 3 or greater (0.4% to 6.9%), Neutropenia (12% to 30.7%)<\/li><li><b>Hepatic:<\/b>Fistula of bile duct<\/li><li><b>Immunologic:<\/b>Complication of infusion<\/li><li><b>Neurologic:<\/b>Cerebral artery occlusion, Cerebral hemorrhage (Glioblastoma, 5%), Hemorrhagic cerebral infarction, Intracranial hemorrhage, Posterior reversible encephalopathy syndrome (up to 1%), Subarachnoid hemorrhage (1% to 5%), Transient ischemic attack<\/li><li><b>Renal:<\/b>Bladder fistula, Fistula from renal pelvis, Nephrotic syndrome, Proteinuria, Grade 3 to 5 (1% to 7%), Serum creatinine raised (Cervical cancer, 16%), Thrombotic microangiopathy<\/li><li><b>Reproductive:<\/b>Female digestive-genital tract fistula (Cervical cancer, 8.2%), Non-menstrual vaginal bleeding (Colorectal carcinoma, 4%), Vaginal fistula finding<\/li><li><b>Respiratory:<\/b>Bronchopleural fistula, Hemoptysis, Interstitial pneumonia, Perforation of nasal septum, Pulmonary hemorrhage (Non-small cell lung cancer, 4% to 31%), Pulmonary hypertension<\/li><li><b>Other:<\/b>Angioedema, Eye<\/li><\/ul>"},"6":{"id":"jw2cs6","title":"Drug Name Info","sub":{"0":{"id":"jw2cs6b17","title":"US Trade Names","mono":"Avastin<br\/>"},"2":{"id":"jw2cs6b19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"jw2cs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jw2cs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jw2cs7","title":"Mechanism Of Action","mono":"Bevacizumab, a recombinant humanized monoclonal IgG1 antibody, binds to vascular endothelial growth factor (VEGF) and inhibits the interaction of VEGF to Flt1 and KDR receptors on the surface of endothelial cells. In the process, it prevents the proliferation of endothelial cells and formation of new blood vessels.<br\/>"},"8":{"id":"jw2cs8","title":"Pharmacokinetics","sub":{"1":{"id":"jw2cs8b24","title":"Distribution","mono":"<ul><li>Vd: (female), 2.66 L<\/li><li>Vd: (male), 3.25 L<\/li><\/ul>"},"4":{"id":"jw2cs8b27","title":"Elimination Half Life","mono":"Approximately 20 days (range 11 days to 50 days) <br\/>"}}},"9":{"id":"jw2cs9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>do not shake vial; discard unused portion; dilute in 100 mL NS; infusions should not be mixed or administered with dextrose-containing solutions<\/li><li>diluted solution may be stored at 2 to 8 degrees C (36 to 46 degrees F) for up to 8 hours; although it is preferable to use the product immediately after dilution to prevent microbial growth, if diluted with NS for injection, chemical and physical stability has been demonstrated for up to 48 hours if stored between 2 and 30 degrees C<\/li><li>administer as IV infusion only; do not administer as IV push or IV bolus<\/li><li>initially infuse over 90 minutes; if tolerated, shorten second infusion to 60 minutes; if tolerated, shorten subsequent infusions to 30 minutes<\/li><\/ul>"},"10":{"id":"jw2cs10","title":"Monitoring","mono":"<ul><li>evidence of tumor response is indicative of efficacy<\/li><li>proteinuria by dipstick urine analysis and serial urinalyses during bevacizumab therapy<\/li><li>patients with a 2+ or greater urine dipstick reading should have a 24 hour urine collection performed<\/li><li>blood pressure every 2 to 3 weeks during therapy<\/li><\/ul>"},"11":{"id":"jw2cs11","title":"How Supplied","mono":"<b>Avastin<\/b><br\/>Intravenous Solution: 25 MG\/ML<br\/>"},"12":{"id":"jw2cs12","title":"Toxicology","sub":[{"id":"jw2cs12b31","title":"Clinical Effects","mono":"<b>BEVACIZUMAB<\/b><br\/>OVERDOSE: Limited overdose data available. Overdose effects are expected to be an extension of adverse effects reported with therapeutic use. At 20 mg\/kg IV (the highest dose tested), severe headache was reported. ADVERSE EFFECTS: COMMON: Vomiting, stomatitis, asthenia, abdominal pain, headache, neutropenia, proteinuria, dizziness, upper respiratory infection, dyspnea, and epistaxis. SEVERE: Hypertension, diarrhea, and leukopenia. SERIOUS: Arterial thromboembolism, hemorrhage, GI hemorrhage, congestive heart failure, hypertensive crisis, gastrointestinal perforation, wound dehiscence, nephrotic syndrome, nasal septum perforation, and hemoptysis (sometimes fatal). Reversible posterior leukoencephalopathy syndrome (headache, seizure, lethargy, confusion, blindness, visual disturbances, hypertension and fluid retention) has also been reported. <br\/>"},{"id":"jw2cs12b32","title":"Treatment","mono":"<b>BEVACIZUMAB<\/b><br\/><ul><li>Decontamination: Administered intravenously; ingestion is unlikely.<\/li><li>Hypertensive episode: Mild to moderate hypertension (no end organ damage) generally does not require treatment. For severe hypertension with evidence of end organ damage, a short acting titratable agent such as nitroprusside is preferred.<\/li><li>Myelosuppression: Filgrastim 5 mcg\/kg\/day subcutaneously or IV over 15 to 30 min, or sargramostim 250 mcg\/m(2)\/day infused over 4 hours for severe neutropenia.<\/li><li>Support: Treatment is symptomatic and supportive. Supportive antiemetic and antidiarrheal agents may be indicated to manage symptoms.<\/li><li>Monitoring of patient: Monitor fluid and electrolytes in patients with signs and symptoms of dehydration or severe vomiting or diarrhea. Monitor vital signs and CBC with differential and platelet count.<\/li><\/ul>"},{"id":"jw2cs12b33","title":"Range of Toxicity","mono":"<b>BEVACIZUMAB<\/b><br\/>TOXICITY: A specific toxic dose has not been determined. The highest dose tested in humans was 20 mg\/kg IV; headache was reported in 9 of 16 patients. THERAPEUTIC: ADULT: For treatment of metastatic colon or rectal cancer, 5 to 10 mg\/kg as an IV infusion every 14 days. For non-squamous, non-small cell lung cancer, 15 mg\/kg as an IV infusion every 3 weeks. For metastatic breast cancer, 10 mg\/kg IV infusion every 14 days. PEDIATRIC: The safety and efficacy of bevacizumab in pediatric patient have not been established. <br\/>"}]},"13":{"id":"jw2cs13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to immediately report impaired wound healing, unusual bleeding, or signs\/symptoms of gastrointestinal perforation (fever, persistent or severe abdominal pain, nausea, constipation, vomiting).<\/li><li>Warn patient to report sign\/symptoms of thrombotic events, including a cerebral infarction, TIA, myocardial infarction, or angina.<\/li><li>Recommend female patient use reliable contraception to avoid pregnancy during therapy and for at least 6 months after therapy.<\/li><li>Drug may cause epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain, and exfoliative dermatitis.<\/li><li>Drug may cause ovarian failure (amenorrhea lasting 3 months or longer).<\/li><li>Advise patient to immediately report signs\/symptoms of reversible posterior leukoencephalopathy syndrome (headache, seizure, lethargy, confusion, blindness, other visual\/neurologic disturbances).<\/li><\/ul>"}}}